MedTrace Logo

The Effect of Remifentanil on the Objectively Measured Pressure Pain Threshold

NCT07568405 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-05

No results posted yet for this study

Summary

It is a clinical study investigating the relationship between objectively measured pain threshold and the need for escalating doses of remifentanyl opioids. This study is expected to include approximately 40 participants.

The aim of the study is to objectively measure the analgesic effect of an increasing dose of opioids just before anesthesia.

Conditions

  • Pain Threshold
  • Surgery
  • Postoperative Pain
  • Intravenous Anesthesia

Interventions

DEVICE

Pressure pain theshold measured under remifentanil (ultiva®) infusion

Upon arrival in the operating room, the patient will undergo standard monitoring, including non-invasive blood pressure, electrocardiography (ECG), pulse oximetry (SpO₂), bispectral index (BIS™), and train-of-four (TOF) monitoring. An intravenous (IV) line will be placed, and crystalloid infusion will be initiated. Mechanical pain threshold will then be assessed using a Medoc algometer. Measurements will be performed on the dorsum of the non-dominant hand. Four measurements will be obtained at different target plasma concentrations of remifentanil(Ultiva®): 0, 1, 2, and 3 ng/mL. Remifentanil will be administered using a target-controlled infusion (TCI) system based on the Minto pharmacokinetic model. Following completion of these measurements, standardized intravenous anesthesia will be induced and maintained using propofol (propolipid®), remifentanil, and rocuronium (B.Braun®). Total perioperative consumption of remifentanil and propofol will be recorded.

DRUG

Postoperative PCA IV morphine (Sterop®) consumption and adverse events history

At the end of the surgical procedure, intravenous acetaminophen 1 g and a 4 mg morphine bolus will be administered. Upon arrival in the post-anesthesia care unit (PACU), pain will be assessed using the visual analogue scale (VAS). During the first 24 postoperative hours, analgesia will be provided via a patient-controlled analgesia (PCA) pump delivering 2 mg intravenous HCL morphine (Sterop®) boluses on demand. The PCA settings will follow a 2/10/20 regimen: 2 mg morphine per demand dose, a 10-minute lockout interval, and a maximum dose of 20 mg over 4 hours. The use of acetaminophen as adjunct analgesia is permitted; however, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), piritramide, and magnesium are prohibited. Pain scores (VAS) will be reassessed at 12 and 24 hours postoperatively. All adverse events (e.g., nausea, delirium) will be monitored and recorded during the 24-hour postoperative period.

Sponsors & Collaborators

  • Université Libre de Bruxelles

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-26
Primary Completion
2026-06-15
Completion
2026-06-15

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07568405 on ClinicalTrials.gov